Brain MRI and Atrophy Scales Predict Alzheimer's Treatment Eligibility
Author Information
Author(s): Zilioli A., Rosenberg A., Mohanty R., Matton A., Granberg T., Hagman G., Lötjönen J., Kivipelto M.
Primary Institution: Karolinska University Hospital
Hypothesis
Can brain MRI volumetry and atrophy rating scales predict amyloid status and eligibility for anti-amyloid treatment in a memory clinic?
Conclusion
Automated analysis of brain atrophy and volumetry outperforms visual assessments in predicting amyloid status and treatment eligibility.
Supporting Evidence
- Automated rating scales showed higher performance than visual assessments.
- Combining MRI data with neuropsychological tests improved predictive accuracy.
- 92 out of 290 patients were amyloid-positive.
Takeaway
Doctors can use brain scans to better understand if patients have Alzheimer's and if they can get new treatments.
Methodology
The study compared visual and automated MRI assessments and combined volumetric data with neuropsychological tests and APOE4 status.
Potential Biases
Potential bias due to the subjective nature of visual assessments and the specific characteristics of the cohort.
Limitations
The study had a relatively small proportion of patients with Alzheimer's compared to those with negative amyloid status.
Participant Demographics
Average age of 59.8 years, 57.6% female, average education of 13.6 years.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI not specified
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website